And it's 20K patients just in Ipsen's territory.....
Where is the 4000 patients coming from? It's likely to be more than 4000.
Hmm... I didn't read the minutes; I should do that. It sounds like they're pointing back at Congress in your statement. I'd watched Bernanke in front of the Congressional panel and in politically correct ways, he tried to suggest that they adopt responsible spending policies but the point was never received. One Congressman said that he disagreed with Bernanke and indirectly said Bernanke didn't know what he was talking about.
IMO, the market is responding to Fed fears of raising interest rates. Other events have transpired too like the US putting a "fivefold" tax increase on steel imports from China which will ripple through anything that uses steel like construction.
Anyone notice that the shares outstanding are like an AT&T Uverse bill; it creeps up every month?
I realized the other day how much of a Frankenstein's Monster Exel is with it's hashed business structure.
There is a 2008 press release that says it specifically. Look at their 10/23/2008 press release tittle: Exelixis Retains Rights to Develop and Commercialize XL184
"As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184.........."
LOL. I could have put more thought into the construction of my sentences which is often the case. Not proof reading before posting produces some awfully constructed thoughts. The "odd" was meant to refer to the 3% and not that you were right.
It's odd but Wilder is right about the 3%. GSK gets a 3% royalty on net sales of any product incorporating cabozantinib because of their prior deal with the series. Foretinib was about 7 nm/L activity vs 0.04 nm/L against vegf2..
AXL: 7 nm/L vs. 8
MET: 3 vs 4 + other isoforms
Cabo was clearly better so GSK bowed out but kept 3% with their initial investment.
The question is what the rest of the deal is. Their is often a part that lets them to move back in in a bigger way.........................
What is happening behind closed doors could influence the price.
GSK knows that "the AXL inhibitor foretinib showed a synergistic effect with HER2 inhibitors and the potential to overcome drug resistance to lapatinib"
Cabozantinib also targets AXL.
I have the same question. Perhaps it'll get pulled after the real numbers come in. I'm assuming they still require P3 to validate the OS and get stat. sig. on the PFS.
Oh, that's right, they were trying to do the approval after P2. Anyone shorting them?
The combo treatment only reached 14.5 months. They didn't report the PFS on the mono treatment that I saw. They're getting denied.
Problem with the where the pipeline is. I would suspect that if they want to sell, they want to know the outcome of CELESTIAL for truer valuation.